AIM ImmunoTech Inc.
AIM
AIM: AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders, viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases and drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer and triple negative metastatic breast cancer. The company is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.
moreShow AIM Financials
Recent trades of AIM by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by AIM's directors and management
Government lobbying spending instances
-
$40,000 Apr 20, 2022 Issue: Pharmacy Health Issues
-
$40,000 Jan 10, 2022 Issue: Pharmacy Health Issues
-
$40,000 Oct 20, 2021 Issue: Pharmacy Health Issues
-
$40,000 Jul 12, 2021 Issue: Health Issues Pharmacy
-
$30,000 Apr 20, 2021 Issue: Pharmacy Health Issues
-
$30,000 Jan 21, 2021 Issue: Health Issues Pharmacy
-
$30,000 Oct 19, 2020 Issue: Health Issues Pharmacy
-
$30,000 Jul 18, 2020 Issue: Health Issues Pharmacy
New patents grants
Federal grants, loans, and purchases
Followers on AIM's company Twitter account
Number of mentions of AIM in WallStreetBets Daily Discussion
Recent insights relating to AIM
Recent picks made for AIM stock on CNBC
ETFs with the largest estimated holdings in AIM
Flights by private jets registered to AIM